Velusetrag - an overview | ScienceDirect Topics
Velusetrag (TD-5108) | 5-HT4R Agonist | MedChemExpress
Frontiers | Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders | Pharmacology
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. - Abstract - Europe PMC
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study - Kuo - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis | Clinical Research Trial Listing ( Gastroparesis ) ( NCT01718938 )
Velusetrag - Wikipedia
Theravance Biopharma :: SEC Filing
Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis | Gut
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
PDF) Velusetrag for the treatment of chronic constipation
Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial - ScienceDirect
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Buy Velusetrag (bt-285965)| THE BioTek
VELUSETRAG
Current developments in pharmacological therapeutics for chronic constipation - ScienceDirect
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
VELUSETRAG
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis - The Lancet Gastroenterology & Hepatology
Prokinetics in Phase II and III stages of development | Download Table
Is Alfasigma late reporting EU clinical trials?
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
PDF) Velusetrag for the treatment of chronic constipation
Velusetrag | C25H36N4O5S - PubChem
